Reference
Tirzepatide: Frequently Asked Questions
This page answers the questions most commonly asked about tirzepatide: what it is, how much weight people lose, how it compares with semaglutide, what happens after stopping, what compounded versions are, what treatment costs, and what the evidence does not establish. Each answer links to the fuller page covering it.
Key takeaways
- Tirzepatide is a weekly dual GIP/GLP-1 agonist approved as Zepbound and Mounjaro.
- SURMOUNT-1 recorded about 20.9% mean weight reduction at 15 mg over 72 weeks.
- SURMOUNT-5 found greater weight reduction than semaglutide in a head-to-head trial.
- SURMOUNT-4 found substantial regain after stopping, making it a long-term treatment.
- Compounded tirzepatide is not FDA approved and has no randomised evidence of its own.
| Drug class | Dual GIP/GLP-1 receptor agonist |
|---|---|
| Dosing | Once weekly by injection |
| Brands | Zepbound (weight), Mounjaro (type 2 diabetes) |
| Pivotal result | About 20.9% at 15 mg (SURMOUNT-1) |
| After stopping | Substantial regain (SURMOUNT-4) |
| Compounded | Not FDA approved; no randomised trial |
What are the questions people most often get wrong?
Three recur. First, that the 20.9% figure is a typical personal result — it is a group mean from a 72-week trial, and individual outcomes vary widely. Second, that compounded tirzepatide is the same product at a lower price — it is a different, unapproved preparation with no trial evidence. Third, that treatment is a course with an endpoint — the withdrawal evidence says otherwise.
Each of these errors is reinforced by marketing, which is why they persist.
What the evidence shows
- Randomised evidence for weight reduction, comparison, and withdrawal.
- Clear regulatory distinction between approved and compounded products.
What the evidence does not show
- That trial means predict individual results.
- That compounded products share the approved product's evidence.
Related: Complete guide · Trial evidence
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does this page cover, and what does it deliberately leave out?
This page addresses Twenty to thirty unique questions with cited concise answers, organised around the primary question of tirzepatide questions. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Twenty to thirty unique questions with cited concise answers | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on tirzepatide questions.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 7 technical terms this page uses, including 503A, 503B, GIP, GLP-1 — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| GIP | Glucose-dependent insulinotropic polypeptide. An incretin hormone released by the small intestine after eating. Tirzepatide activates its receptor alongside the GLP-1 receptor, which is the feature that distinguishes it from single-agonist drugs such as semaglutide. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| endpoint | The outcome a trial is designed to measure. A primary endpoint is specified before the trial begins; secondary and exploratory endpoints carry progressively weaker inferential weight. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
Frequently asked questions
What is tirzepatide?
A once-weekly dual GIP/GLP-1 receptor agonist approved as Zepbound and Mounjaro. See the complete guide.
How much weight will I lose?
Trial means were about 20.9% at 15 mg over 72 weeks; individual results vary widely. See results and timeline.
Is tirzepatide better than semaglutide?
In SURMOUNT-5 it produced greater weight and waist reduction. See the comparison.
What happens if I stop?
SURMOUNT-4 found substantial regain. See stopping tirzepatide.
Is compounded tirzepatide FDA approved?
No. See the regulatory position.
What does it cost?
It depends on brand, insurance, and provider fees. See the cost hub.
What are the side effects?
Predominantly gastrointestinal, concentrated during escalation. See side effects.
Do I need a prescription?
Yes. Tirzepatide is a prescription medicine in every form, including compounded preparations.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.